2022
Immunogenicity and Antibody Titers After BNT162b2 mRNA COVID-19 Vaccine, Breakthrough Infection and Booster
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. Immunogenicity and Antibody Titers After BNT162b2 mRNA COVID-19 Vaccine, Breakthrough Infection and Booster. 2022, a3130-a3130. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3130.Peer-Reviewed Original ResearchBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 vaccineBreakthrough infectionsAntibody titers
2021
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levels